The DCGI office had granted SII permission to manufacture and stock Covovax on May 17. Based on the DCGI s approval, till now, the Pune-based firm has manufactured and stockpiled vaccine doses.
NEW DELHI: An expert panel of India’s Central Drug Authority on Tuesday recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on kids aged 2 to 17 years with certain conditions, official sources said. The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.
“The Subject Expert Committee on Covid-19 deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on kids aged 2 to 17 years,” a source said.
FacebookTwitterLinkedinEMail
Expert panel recommends nod to SII for phase 2/3 trials of Covovax on children aged 2-17 indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.